We’ve all seen it: the media craze about gluten and how it’s terrible for us. Except it generally lacks solid scientific consensus, and like most of these marketing fads,…
Pharmaceuticals
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he put out news claiming…
Neptune Wellness Solutions (NEPT.T) reported today that their phase II expansion at their Sherbrooke, Quebec, facility is online and has received approvals to run product for customers, topping out…
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space…
Mind Medicine (MMED.E) started enrolling candidates for further human safety trial studies of 18-MC, the company’s orally taken ibogaine derivative for the treatment of opioid addiction. Clinical studies for…
Being working class in the United States in the time of Donald Trump is a curious endeavour. The stories coming from some of my friends to the south would…
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business….
Roadman Investments’ (LITT.V) recent acquisition target CLOV Biopharma (CBP) is continuing its research into the potential commercial uses of cedar leaf oil vapour (CLOV), specifically when it comes to…
Soligenix (SNGX.Q), a biopharma company that develops and commercializes products for rare diseases, announced that its RiVax, which is a heat stable ricin toxin vaccine, has received a fast…
If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there….